<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1859">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469491</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0041</org_study_id>
    <nct_id>NCT04469491</nct_id>
  </id_info>
  <brief_title>Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study</brief_title>
  <acronym>COV-NI</acronym>
  <official_title>Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 is causing a serious viral pandemic in terms of health and social impact. To date,
      no treatment has yet demonstrated its efficacy in treating the infectious disease (COVID-19).
      Pulmonary administration of Interferon (IFN) type I is a therapeutic strategy with high
      potential,due to higher local concentrations and minimal adverse effects. Type I interferons
      (including IFN-α and IFN-β) are antiviral defence cytokines and also have the potential to
      negatively modulate IFN Type II and IL-6 dependent cytokine storm, the latter being induced
      in the late forms of COVID-19. In vitro, IFN-β were more effective on COVID-19 than IFN-α. In
      existing preliminary studies, only patients receiving IFN type I modulators have a decrease
      in viral carriage and a rapid reversal. The purpose of this project is to assess in
      hospitalized patients with oxygen for COVID 19, the clinical efficacy on oxygen requirements
      of the addition of inhaled Interferon type I compared to the control arm .
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oxygen requirement score at day 0</measure>
    <time_frame>day 0</time_frame>
    <description>oxygen requirement score at day 0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oxygen requirement score at day 15</measure>
    <time_frame>day 15</time_frame>
    <description>oxygen requirement score at day 15</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation oxygen requirement score between day 0 and day15</measure>
    <time_frame>at day 15</time_frame>
    <description>Variation oxygen requirement score between day 0 and day15</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID-19</condition>
  <condition>INTERFERON</condition>
  <condition>NEBULIZATION</condition>
  <arm_group>
    <arm_group_label>Inhaled IFN arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN (Interferon) pulmonary (Inhalation) + routine care (+/- antibiotics; + appropriate O2 support)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aerosol (WFI water and routine care (+/- antibiotics; + appropriate O2 support).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled type I interferon</intervention_name>
    <description>The interventional arm includes inhaled type I interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days), in addition to standard care.</description>
    <arm_group_label>Inhaled IFN arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WFI water nebulization</intervention_name>
    <description>The interventional arm includes a WFI water nebulization comparator.</description>
    <arm_group_label>Control Arm:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Patient with laboratory-confirmed COVID-19 infection as determined by PCR &lt; 96 h (at
             initial diagnosis or aggravation phase with persistent carriage &lt;96 h)

          -  Inpatients with COVID-19 of any duration, requiring oxygen therapy (mask or mechanical
             ventilation).

          -  Social security coverage

          -  Signed informed consent (by patient or their legally authorized representative)

        Exclusion Criteria:

          -  Hypersensitivity to natural or recombinant interferon-ß

          -  Hypersensitivity to human albumin or mannitol

          -  Recent suicide attempt

          -  Decompensation of liver failure

          -  age &lt; 18 years

          -  Pregnant or nursing.

          -  Patients managed on an outpatient basis (i.e. not initially hospitalized).

          -  Parenteral IFN treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe Lanoix, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Philippe Lanoix, MD</last_name>
    <phone>(33)322668813</phone>
    <email>lanoix.jean-philippe@chu-amiens.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurélien Mary, MD</last_name>
    <phone>(33)22087140</phone>
    <email>mary.aurelien@chu-amiens.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Philippe Lanoix, MD</last_name>
      <phone>(33)3 22 66 88 13</phone>
      <email>lanoix.jean-philippe@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Aurélien Mary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Brazier, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Luc Jean Luc Schmit, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>INTERFERON</keyword>
  <keyword>NEBULIZATION</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon Type I</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

